<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02702999</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-16-0084</org_study_id>
    <nct_id>NCT02702999</nct_id>
  </id_info>
  <brief_title>Determination of Abnormal Fetal Growth or Amniotic Fluid With Third Trimester Ultrasounds in Uncomplicated Pregnancies: A Randomized Trial</brief_title>
  <acronym>UP</acronym>
  <official_title>Determination of Abnormal Fetal Growth or Amniotic Fluid With Third Trimester Ultrasounds in Uncomplicated Pregnancies: A Randomized Trial (UP Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see whether women at a gestational age of 30 weeks or more
      without comorbidities, does performance of serial 3rd trimester growth ultrasounds increase
      the frequency of identifying abnormalities in fetal growth or amniotic fluid, when compared
      with women who only receive indicated ultrasounds?
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with fetal growth restriction</measure>
    <time_frame>30 weeks gestational age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with large for gestational age fetuses</measure>
    <time_frame>30 weeks gestational age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participates with oligohydraminos</measure>
    <time_frame>30 weeks gestational age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participates with hydraminos</measure>
    <time_frame>30 weeks gestational age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with fetal growth restriction</measure>
    <time_frame>34 weeks gestational age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with large for gestational age fetuses</measure>
    <time_frame>34 weeks gestational age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participates with oligohydraminos</measure>
    <time_frame>34 weeks gestational age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participates with hydraminos</measure>
    <time_frame>34 weeks gestational age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with fetal growth restriction</measure>
    <time_frame>38 weeks gestational age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with large for gestational age fetuses</measure>
    <time_frame>38 weeks gestational age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participates with oligohydraminos</measure>
    <time_frame>38 weeks gestational age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participates with hydraminos</measure>
    <time_frame>38 weeks gestational age</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Neonatal Morbidity</measure>
    <time_frame>From time of delivery to discharge (average time of discharge is 4 days after delivery)</time_frame>
    <description>Presence of morbidity is indicated by one or more of the following: 1) Apgar score &lt; 5 at 5 min; 2) umbilical arterial pH &lt; 7.00; 3) intraventricular hemorrhage grade III or IV; 4) periventricular leukomalacia; 5) intubation for over 24 hrs; 6) necrotizing enterocolitis grade 2 or 3; 7) stillbirth; or 8) death within 28 days of birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Maternal Morbidity</measure>
    <time_frame>From time of delivery to discharge (average time of discharge is 4 days after delivery)</time_frame>
    <description>The presence of morbidity is indicated by one of more of the following: 1) chorioamnionitis; 2) cesarean delivery in labor; 3) wound infection; 4) transfusion; 5) deep venous thrombus or pulmonary embolism; 6) admission to intensive care unit; or 7) death.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Uncomplicated Pregnancy</condition>
  <condition>Abnormal Fetal Growth or Fluid</condition>
  <arm_group>
    <arm_group_label>Routine third trimester care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Routine third trimester care with clinically-indicated ultrasound (control)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Serial third trimester ultrasound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Clinically-indicated ultrasound</intervention_name>
    <description>Routine third trimester care with clinically-indicated ultrasound (control)</description>
    <arm_group_label>Routine third trimester care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Serial third trimester ultrasound</intervention_name>
    <description>Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).</description>
    <arm_group_label>Serial third trimester ultrasound</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Maternal age of 18 at the time of consent

          -  Singleton gestation

        Exclusion Criteria:

          -  First sonographic examination after 20 weeks

          -  Women with any of the following co-morbidities: Autoimmune disorders (antiphospholipid
             antibody, lupus, rheumatoid arthritis, scleroderma), Cerclage in the index pregnancy,
             Diabetes mellitusâ€”gestational or pre-gestational, Hematologic disorders (coagulation
             defects, sickle cell disease, thrombocytopenia, thrombophilia), Hypertension (chronic
             or pregnancy induced) before enrollment, HIV (human immunodeficiency virus),
             Institutionalized individuals (prisoners), Prior obstetric history of: [1)
             intrauterine growth restriction, 2) preterm birth before 34 weeks, 3) severe
             preeclampsia], eclampsia, HELLP syndrome, and 4) stillbirth after 24 weeks or neonatal
             death, Preterm labor or ruptured membranes before enrollment, Psychiatric disorder
             (bipolar, depression) on medication, Placenta previa / 3rd trimester bleeding, Renal
             insufficiency (serum creatinine &gt; 1.5 mg/dL), Restrictive lung disease, Fetal red
             blood cell isoimmunization, Seizure disorder on medication, Thyroid disease on
             medication, Body Mass Index (BMI) above 40 kg/m2

          -  Major fetal Anomaly including: anencephaly, spina bifida, bilateral renal agenesis,
             cystic hygroma with hydrops, diaphragmatic hernia, or congenital heart defects

          -  Unable to understand consent in English or Spanish
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olaide A Ashimi Balogun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olaide A Ashimi Balogun, MD</last_name>
    <phone>713-500-6421</phone>
    <email>olaide.a.ashimi@uth.tmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UT Physicians</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olaide A Ashimi Balogun, MD</last_name>
      <phone>972-922-9218</phone>
      <email>olaide.a.ashimi@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Suneet P Chauhan, MD</last_name>
      <email>Suneet.p.chauhan@uth.tmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Texas at Houston Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olaide A Ashimi Balogun, MD</last_name>
      <phone>713-500-6421</phone>
      <email>olaide.a.ashimi@uth.tmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2016</study_first_submitted>
  <study_first_submitted_qc>March 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <last_update_submitted>November 21, 2016</last_update_submitted>
  <last_update_submitted_qc>November 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Olaide Ashimi Balogun</investigator_full_name>
    <investigator_title>Fellow</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

